<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119751</url>
  </required_header>
  <id_info>
    <org_study_id>IIT4</org_study_id>
    <nct_id>NCT05119751</nct_id>
  </id_info>
  <brief_title>Vestibular Versus Sublingual Route of AIT Tablets</brief_title>
  <official_title>An Investigator-initiated Single Center Randomised Clinical Pilot Study to Compare Tolerability of the Sublingual Versus Vestibular Administration Routes for Birch Pollen, Grass Pollen, Ragweed Pollen, or House Dust Mite Allergy Immunotherapy (AIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Spécialisée en Allergies de la Capitale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Spécialisée en Allergies de la Capitale</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the tolerability of the vestibular administration route of birch pollen, grass&#xD;
      pollen, ragweed pollen, and house dust mite (HDM) AIT tablets compared with the sublingual&#xD;
      route in adult subjects with allergic rhinitis/conjunctivitis (AR/C)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center randomised controlled pilot trial conducted in Canada. Subjects will&#xD;
      be randomised (1:1) to receive vestibular or sublingual birch pollen, grass pollen, ragweed&#xD;
      pollen, or HDM AIT in tablet form for 28±4 days, followed by 28±4 days of sublingual&#xD;
      administration only. The ratio will be ~ 1:1:1:1 for tree-, grass-, ragweed-pollen and HDM&#xD;
      AIT tablet treatments, with a minimum of 30 patients in each allergen group for a total of&#xD;
      approximately 200 randomised subjects.&#xD;
&#xD;
      Adults (18-65 years of age) who demonstrate birch, grass, ragweed, or HDM allergen skin prick&#xD;
      test (SPT) positivity and with a history of birch pollen-, grass pollen-, ragweed pollen-, or&#xD;
      HDM allergen-induced AR/C, with or without asthma are eligible for the trial.&#xD;
&#xD;
      Data for the primary endpoint of severity of treatment-related AEs will be collected during&#xD;
      the first 28±4 days of treatment. The trial consists of 3 trial periods: a screening period&#xD;
      (up to 12 weeks), a randomised two-arm treatment period of 28±4 days, and a single-arm&#xD;
      sublingual treatment follow-up period of 28±4 days.&#xD;
&#xD;
      Screening period: Subjects will be evaluated based on eligibility criteria at visit 1 (V1).&#xD;
&#xD;
      Treatment period: the randomisation visit will be performed (V2) and eligible subjects&#xD;
      randomised in a 1:1 ratio to vestibular or sublingual AIT tablet with the appropriate&#xD;
      allergen for their allergen sensitization. At day 28±4, a visit will be conducted (V3) for&#xD;
      all subjects previously receiving vestibular AIT to be switched to sublingual AIT with the&#xD;
      appropriate allergen for their allergen sensitization. Subjects previously receiving&#xD;
      sublingual AIT will remain on their previous treatment. All subjects will discontinue&#xD;
      treatment after 56±8 days on treatment (V4). Subjects who would like to continue the&#xD;
      sublingual immunotherapy tablets will be permitted to do so based on physician judgment and&#xD;
      own expense but will no longer be part of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>First month of treatment is taken the vestibular route and the following the sublingual</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability (severity and number of adverse events AEs)</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the tolerability of the vestibular administration route</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Birch allergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomised (1:1) to receive vestibular or sublingual birch pollen&#xD;
once daily tree 12 SQ-Bet AIT tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grass allergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomised (1:1) to receive vestibular or sublingual grass pollen&#xD;
grass 2800 BAU AIT tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ragweed allergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomised (1:1) to receive vestibular or sublingual ragweed pollen ragweed 12 Amb a 1-U AIT Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>House dust mite allergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomised (1:1) to receive vestibular or sublingual HDM&#xD;
HDM 12 SQ-HDM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tree 12 SQ-Bet</intervention_name>
    <description>DAILY DOSE OF AIT TABLET</description>
    <arm_group_label>Birch allergy</arm_group_label>
    <other_name>ITULATEK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRASS 2800 BAU</intervention_name>
    <description>DAILY DOSE OF AIT TABLET</description>
    <arm_group_label>Grass allergy</arm_group_label>
    <other_name>GRASTEK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAGWEED 12 AMB A 1-U</intervention_name>
    <description>DAILY DOSE OF AIT TABLET</description>
    <arm_group_label>ragweed allergy</arm_group_label>
    <other_name>RAGWITEK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM 12 SQ-HDM</intervention_name>
    <description>DAILY DOSE OF AIT TABLET</description>
    <arm_group_label>House dust mite allergy</arm_group_label>
    <other_name>ACARIZAX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained before any trial related procedures are performed&#xD;
&#xD;
               -  Male or female of any race/ethnicity aged 18-65 years at the time of signing the&#xD;
                  informed consent&#xD;
&#xD;
               -  A clinically relevant history of birch pollen-, grass pollen-, ragweed pollen-,&#xD;
                  or HDM allergen-induced AR/C with or without asthma requiring treatment during&#xD;
                  the respective allergen season for birch pollen, grass pollen, or ragweed pollen,&#xD;
                  or perennial AR/C for HDM.&#xD;
&#xD;
               -  Positive SPT (5 mm wheal size or greater) to birch pollen, timothy grass pollen,&#xD;
                  ragweed pollen, or Dermatophagoides pteronyssinus/farinae within the previous 12&#xD;
                  months&#xD;
&#xD;
               -  A device with daily access to the internet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Previous SLIT-tablet treatment&#xD;
&#xD;
               -  Subcutaneous AIT treatment for the sensitized allergen within less than 5 years&#xD;
                  of screening&#xD;
&#xD;
               -  Severe acute or chronic oral inflammation. Subjects with acute oral inflammation&#xD;
                  may be randomised when the condition has been resolved&#xD;
&#xD;
               -  A history or diagnosis of eosinophilic oesophagitis&#xD;
&#xD;
               -  A relevant history of systemic allergic reaction e.g. anaphylaxis with&#xD;
                  cardiorespiratory symptoms, generalised urticaria or severe facial angioedema&#xD;
                  that in the opinion of the investigator may constitute an increased safety&#xD;
                  concern&#xD;
&#xD;
               -  Unstable, severe asthma (FEV1 &lt;70% of predicted value after adequate&#xD;
                  pharmacologic treatment) at randomisation&#xD;
&#xD;
               -  Currently taking beta-blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remi Gagnon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Spécialisée en Allergies de la Capitale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Claude Joly, RN</last_name>
    <phone>418-659-7741</phone>
    <phone_ext>243</phone_ext>
    <email>mcjoly@csacqc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique specialisee en allergie de la capitale</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Potvin, BAA</last_name>
      <phone>418-659-7741</phone>
      <phone_ext>228</phone_ext>
      <email>lpotvin@csacqc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Claude Joly, RN</last_name>
      <phone>418-659-7741</phone>
      <phone_ext>243</phone_ext>
      <email>mcjoly@csacqc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Remi Gagnon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

